Literature DB >> 19100873

Identification of novel candidate protein biomarkers for the post-polio syndrome - implications for diagnosis, neurodegeneration and neuroinflammation.

Henrik Gonzalez1, Jan Ottervald, Kerstin C Nilsson, Niclas Sjögren, Tasso Miliotis, Helena Von Bahr, Mohsen Khademi, Bodil Eriksson, Sven Kjellström, Akos Vegvari, Robert Harris, György Marko-Varga, Kristian Borg, Johan Nilsson, Thomas Laurell, Tomas Olsson, Bo Franzén.   

Abstract

Survivors of poliomyelitis often develop increased or new symptoms decades after the acute infection, a condition known as post-polio syndrome (PPS). The condition affects 20-60% of previous polio patients, making it one of the most common causes of neurological deficits worldwide. The underlying pathogenesis is not fully understood and accurate diagnosis is not feasible. Herein we investigated whether it was possible to identify proteomic profile aberrations in the cerebrospinal fluid (CSF) of PPS patients. CSF from 15 patients with well-defined PPS were analyzed for protein expression profiles. The results were compared to data obtained from nine healthy controls and 34 patients with other non-inflammatory diseases which served as negative controls. In addition, 17 samples from persons with secondary progressive multiple sclerosis (SPMS) were added as relevant age-matched references for the PPS samples. The CSF of persons with PPS displayed a disease-specific and highly predictive (p=0.0017) differential expression of five distinct proteins: gelsolin, hemopexin, peptidylglycine alpha-amidating monooxygenase, glutathione synthetase and kallikrein 6, respectively, in comparison with the control groups. An independent ELISA confirmed the increase of kallikrein 6. We suggest that these five proteins should be further evaluated as candidate biomarkers for the diagnosis and development of new therapies for PPS patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19100873     DOI: 10.1016/j.jprot.2008.11.014

Source DB:  PubMed          Journal:  J Proteomics        ISSN: 1874-3919            Impact factor:   4.044


  12 in total

Review 1.  Peptidylgycine α-amidating monooxygenase and copper: a gene-nutrient interaction critical to nervous system function.

Authors:  Danielle Bousquet-Moore; Richard E Mains; Betty A Eipper
Journal:  J Neurosci Res       Date:  2010-09       Impact factor: 4.164

2.  IVIG treatment in post-polio patients: evaluation of responders.

Authors:  Gunilla Ostlund; Lisbet Broman; Lars Werhagen; Kristian Borg
Journal:  J Neurol       Date:  2012-05-17       Impact factor: 4.849

3.  Differential expression of multiple kallikreins in a viral model of multiple sclerosis points to unique roles in the innate and adaptive immune response.

Authors:  Michael Panos; George P Christophi; Moses Rodriguez; Isobel A Scarisbrick
Journal:  Biol Chem       Date:  2014-09       Impact factor: 3.915

4.  Kallikrein cascades in traumatic spinal cord injury: in vitro evidence for roles in axonopathy and neuron degeneration.

Authors:  Maja Radulovic; Hyesook Yoon; Nadya Larson; Jianmin Wu; Rachel Linbo; Joshua E Burda; Eleftherios P Diamandis; Sachiko I Blaber; Michael Blaber; Michael G Fehlings; Isobel A Scarisbrick
Journal:  J Neuropathol Exp Neurol       Date:  2013-11       Impact factor: 3.685

Review 5.  Peptidylglycine α-amidating monooxygenase as a therapeutic target or biomarker for human diseases.

Authors:  David J Merkler; Aidan J Hawley; Betty A Eipper; Richard E Mains
Journal:  Br J Pharmacol       Date:  2022-02-28       Impact factor: 9.473

6.  Update on current and emerging treatment options for post-polio syndrome.

Authors:  Elisabeth Farbu
Journal:  Ther Clin Risk Manag       Date:  2010-07-21       Impact factor: 2.423

7.  Kallikrein 6 regulates early CNS demyelination in a viral model of multiple sclerosis.

Authors:  Isobel A Scarisbrick; Hyesook Yoon; Michael Panos; Nadya Larson; Sachiko I Blaber; Michael Blaber; Moses Rodriguez
Journal:  Brain Pathol       Date:  2012-03-21       Impact factor: 6.508

Review 8.  60 YEARS OF POMC: From POMC and α-MSH to PAM, molecular oxygen, copper, and vitamin C.

Authors:  Dhivya Kumar; Richard E Mains; Betty A Eipper
Journal:  J Mol Endocrinol       Date:  2015-12-14       Impact factor: 5.098

9.  Intravenous immunoglobulin treatment of the post-polio syndrome: sustained effects on quality of life variables and cytokine expression after one year follow up.

Authors:  Henrik Gonzalez; Mohsen Khademi; Kristian Borg; Tomas Olsson
Journal:  J Neuroinflammation       Date:  2012-07-09       Impact factor: 8.322

10.  Cerebrospinal fluid biomarker candidates associated with human WNV neuroinvasive disease.

Authors:  Christophe Fraisier; Anna Papa; Samuel Granjeaud; Rogier Hintzen; Byron Martina; Luc Camoin; Lionel Almeras
Journal:  PLoS One       Date:  2014-04-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.